Immunovia Strengthens Management Team Ahead of its Commercial Launch of IMMray™ PanCan-d
LUND, SWEDEN – Immunovia AB (publ) (“Immunovia”) a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray™ for the early detection of cancer, today announced the strengthening of the Company’s management team with two very experienced executives. Hans Christian Pedersen has been appointed Vice-President of Business Development, succeeding Henrik Winther, and Dr. Peter Schultz-Knappe has been appointed Chief Technology Officer (CTO). Henrik Winther, Senior Vice-President of Business Development, is